

GRANT AGREEMENT



Parties to this agreement:

Diabetesforeningen
 Att: Tanja Thybo
 Stationsparken 24, st.tv.
 2600 Glostrup
 CVR: 35 23 15 28
 (“Recipient”)

Novo Nordisk Denmark A/S
 Att.: Tina Damgaard
 Kay Fiskers Plads 10, 7 floor
 2300 København S
 CVR No. 38180045

(“Novo Nordisk”)

1. Summary

1.1 Recipient’s request for support. The appendix titled “Recipient’s request for support” details the specifics of the Recipient’s activity(ies) (“the Activity”) supported by the grant and purpose of the Activity. Novo Nordisk has decided to support the recipient’s request as part of its commitment to advance healthcare and science.

Title of Activity	Financial support to make new report (publication) on the disease burden of Type 1 and Type 2 diabetes in Denmark.
Purpose of the Activity	The recipient shall use the grant only for the healthcare-related purpose of producing new report (publication) on the disease burden of Type 1 and Type 2 diabetes in Denmark. <i>The recipient’s purpose must not involve promotion of any pharmaceutical product.</i>
Grant amount	Novo Nordisk will provide 145.000 DKK including added tax if applicable, to support the Recipient’s request. Novo Nordisk will not make any non-financial transfers of value.
Agreement Duration	This agreement starts on 1/12/2024 and expires after all obligations are fulfilled, unless terminated earlier.

2. Recipient’s Duties

2.1 Compliance with law and ethics. The Recipient shall comply with all applicable laws, rules, regulations, and professional standards, including those related to ethical business practices, bribery and corruption, among others. The Recipient will hold Novo Nordisk harmless against any claim or suit that arises in relation to any deviation from the above mentioned that is not due to any act or omission by Novo Nordisk.

2.2 Carry out the Activity with proper conduct. The Recipient shall carry out the Activity independently and without Novo Nordisk influence, and in compliance with Novo Nordisk standards and industry codes such as IFPMA and EFPIA. Such proper conduct of the Activity includes, but is not limited to:

No use of funds for entertainment	Do not use the grant for leisure or social activities
No use of product names	Do not use trade and advertising names of medicinal products in any content or materials used for the Activity
Select qualified participants	Apply appropriate criteria to select participants in the Activity, including that any speakers, facilitators, and chairpersons are experts in the professional fields relevant to the Activity

Reasonable payment	If grant is used to provide payments to third parties, apply a reasonable rate, including following Fair Market Value for any payments to Healthcare Professionals (hereinafter refer to as 'HCPs') and patients
Reasonable choice of venue	Hold activities in a location suitable for business meetings with modest hospitality
Reasonable travel	If grant is used for Activity-related travel, carry out within reasonable time and cost

2.3 Internal approvals. The Recipient shall obtain all necessary approvals related to the receipt of the grant.

2.4 Provide documentation within 1 month. The Recipient shall provide Novo Nordisk with documentation that the grant was used for its intended purpose, within 1 month of completion of the Activity. Novo Nordisk may request additional detailed documentation as needed.

2.5 Inform Novo Nordisk of changes. The Recipient shall inform Novo Nordisk of any changes affecting the request for support. Novo Nordisk may increase, decrease, withdraw or require full or partial repayment of the grant as a result of the changes. In the case of repayment, the Recipient shall refund Novo Nordisk the requested amount within 14 days.

2.6 Refund unspent amounts. The Recipient shall refund Novo Nordisk any amounts not spent for the requested purposes, within 14 days after complete documentation of the Activity is provided.

2.7 Disclose Novo Nordisk as grant provider. The Recipient shall mention Novo Nordisk as the provider of the grant in educational materials developed through the grant, as well as in any public communications or advertising related to the Activity.

2.8 Required public disclosures. Novo Nordisk will publish information relating to this grant on Novo Nordisk's website (www.novonordisk.dk). According to Danish regulation Novo Nordisk may in addition make this Grant Agreement publicly available. The Recipient shall provide to Novo Nordisk upon request all information reasonably required for Novo Nordisk's compliance with legal and/or regulatory requirements for contracting, tracking and disclosing transfer of values (ToVs) to the Recipient.

The Recipient will publish information on the grant on the Recipient's webpage. The information includes the grants amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Grant. The information must be publicly available for at least two (2) years.

2.9 Do not use Novo Nordisk branding without approval. The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials without written approval of the use from Novo Nordisk.

2.10 Allow Novo Nordisk to use Recipient's logo. The Recipient permits Novo Nordisk to use the Recipient's logo, trademarks or other corporate identity marks in any public communications or advertising related to Novo Nordisk's grant.

3. Payment and Invoice Requirements

3.1 Payment after receipt of invoice. Novo Nordisk will send payment after receipt of invoice to the Recipient's bank account via electronic transfer within 30 days of receiving a complete invoice. Send completed PDF invoice to: AP-Novo-Repas@novonordisk.com. Include the below information on the invoice:

- Recipient name and address
- Bank account for electronic payment: Account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU, ABA/ACH in USA)
- Date of invoice
- The Title of Activity and dates of activities covered by the invoice
- Grant amount payable
- VAT or other tax amount payable (include separately from payment amount)
- Name of Novo Nordisk entity and address as stated in the introduction of this Agreement
- Novo Nordisk recipient of invoice as included below:

Name of Novo Nordisk invoice recipient Benedicte Rigmor Schiersing (BCRS@novonordisk.com)

4. Other Terms and Conditions

- 4.1 **Disclosure of Transfers of Value.** To comply with applicable transparency requirements, Novo Nordisk will collect and may disclose personal information, transfers of value and details of its payment to Healthcare Professionals (“HCPs”) and Healthcare Organizations (“HCOs”). In addition to the payment amount, such disclosure may also include: Name, address, contact details, nature of relationship with Novo Nordisk, tax number or unique identifier.
 - 4.2 **No conflict of interest.** Recipient states it is not aware of any conflict of interest related to its acceptance of the grant and shall promptly inform Novo Nordisk if such conflict of interest is discovered.
 - 4.3 **Compliance hotline.** The Recipient can report suspected misconduct through the Novo Nordisk compliance hotline. Information about using the hotline and examples of what to report can be found at [Report suspected misconduct \(novonordisk.com\)](#).
 - 4.4 **No incentive to prescribe or recommend.** The payments made by Novo Nordisk indicate no incentive or obligation for the Recipient to prescribe, recommend or otherwise support Novo Nordisk’s products or services.
 - 4.5 **Termination for breach.** Either party may terminate this contract immediately upon material breach by the other party.
 - 4.6 **Governing Law and Dispute Resolution.** The laws of Denmark govern this agreement, disregarding choice of law rules. If a dispute cannot be settled by negotiation between parties, it will be settled by the ordinary courts in that country.
5. **Attachments**
The following attachments are part of this agreement

Attachment A: Recipient’s request for support (application form, letter or email), with detailed program plan, timeline and budget

6. Agreed to and Accepted by:

Date: 10 december 2024


Date: 10 December 2024

On behalf of Recipient:

On behalf of Novo Nordisk:

DocuSigned by:

21B32853305441A...

Signed by:

487906ACBEF1487...

Name: Claus Richter

Name: Tina Damgaard

Title: CEO

Title: Medical Manager

Appendix A: Recipient's Request for Support

1. Copy of the Recipient's grant request

12. november 2024



Til
CTIK, Christian Klyver Tikkanen
Novo Nordisk Danmark A/S

Ansøgning om støtte til at bestemme Sygdomsbyrden for type 1- og type 2-diabetes

Diabetesforeningen har indgået et samarbejde med Statens Institut for Folkesundhed, Syddansk Universitet om at kortlægge sygdomsbyrde af type 1-diabetes og type 2-diabetes.

Sygdomsbyrde af type 1-diabetes

Forekomsten af type 1-diabetes (T1DM) vil blive præsenteret både samlet og opdelt på henholdsvis aldersgrupper og køn. For at undersøge social ulighed i forekomsten af T1DM laves opgørelserne også opdelt på længst fuldførte uddannelse for både mænd og kvinder.

Desuden belyses den ekstra byrde, som T1DM medfører i forhold til en referencepopulation med samme køn, alder og længst fuldførte uddannelse, der ikke har T1DM. Byrden opgøres i forhold til kontakter i sundhedsvæsenet herunder brug af øjenlæge og fodterapeut, langvarigt sygefravær, nytilkendte førtidspensioner samt økonomiske konsekvenser givet ved omkostninger til kontakter i sundhedsvæsenet og produktionstab ved langvarigt sygefravær eller varig afgang fra arbejdsmarkedet grundet førtidspension eller død. Projektet giver således svar på f.eks. hvor mange ekstra antal nytilkendte førtidspensioner per år, der finder sted blandt personer med T1DM i forhold til blandt personer i referencepopulationen, der ikke har T1DM, men ellers er sammenlignelig i forhold til alder, køn og længst fuldførte uddannelse. Der er altså fokus på den ekstra byrde, som personer med T1DM oplever.

Endelig ønsker vi også at undersøge, om der er social ulighed i byrden ved T1DM. Dette belyses ved at beregne den ekstra byrde blandt personer på tværs af længst fuldførte uddannelse opdelt på grundskole, erhvervsfaglig/ gymnasial uddannelse og videregående uddannelse. Herved kan projektet give svar på, hvor stor en andel af den ekstra byrde f.eks. i forhold til ekstra antal nytilkendte førtidspensioner pr. år, der finder sted inden for de enkelte uddannelsesgrupper. Hertil vil det være muligt at beregne hvor meget af den ekstra byrde ved T1DM, der ville være undgået eller tillagt, hvis alle personer med T1DM havde samme forekomst af en given byrde som personer med videregående uddannelse.

Analyserne vil blive baseret på nyest tilgængelige data fra registre, sandsynligvis året 2021.

Stationsparken 24, st. tv.
2600 Glostrup

Telefon 66 12 90 06

Fax 65 91 49 08
info@diabetes.dk
www.diabetes.dk

CVR-nr. DK-35 23 15 28

Sygdomsbyrde af type 2-diabetes

Samme analyser som nævnt oven for vil blive gennemført for personer med type 2-diabetes. Disse beregninger vil også være baseret på nyest tilgængelige data fra registre.

Afrapportering

Afrapportering af resultater vil ske ved både i form af en kortfattet rapport på danske samt en videnskabelig artikel på engelsk.

Organisering

Projektgruppen vil bestå af forsker Isabelle Pascale Mairey, videnskabelig assistent Mattias Højgaard Toftholm og professor Lau Caspar Thygesen. Isabelle Pascale Mairey og Lau Caspar Thygesen var begge forfattere til "Sygdomsbyrden i Danmark" udgivet i 2023.

Det samlede budget lyder på 465.000 kroner. Budget er vedhæftet. Hertil kommer interne ressourcer på 0,2 FTE, som dækkes af Diabetesforeningen.

Arbejdet starter **1. december 2024** og munder ud i en rapport samt manuskriptet til en videnskabelig publikation **Q2 2025**.

Diabetesforeningen har mundtligt tilsagn fra to medicinalvirksomheder om støtte på i alt DKK 245.000. Vi søger derfor Novo Nordisk Danmark A/S om et sponsorat til hjælp til finansiering af projektet ifølge nedenstående model:

Novo Nordisk Danmark A/S	145.000 DKK
Medicinalfirma 1	145.000 DKK
Medicinalfirma 2	100.000 DKK
Diabetesforeningen	75.000 DKK
I alt	465.000 DKK
Desuden Diabetesforeningen	0.2 FTE

Beløbet tillægges moms.

Med venlig hilsen



Tanja Thybo

Tlf.: +45 41 91 88 11
tth@diabetes.dk

2. Activity timelines and budget

Budget	2025	
	Applied	
LØN	Md	DKK
Videnskabelig assistent /Mattias Hø	3,0	137.000
Professor / Lau Caspar Thygesen	0,5	45.000
Forsker / Isabelle Pascale Bodi Mair	2,0	135.000
LØN I ALT	5,5	317.000
DRIFT		DKK
Data		30.000
Publicering		25.000
DRIFT I ALT		55.000
OMKOSTNINGER I ALT	5,5	372.000
Overhead		93.000
BUDGET I ALT	5,5	465.000

